Limits...
Thiazolidinediones are associated with a reduced risk of COPD exacerbations.

Rinne ST, Liu CF, Feemster LC, Collins BF, Bryson CL, O'Riordan TG, Au DH - Int J Chron Obstruct Pulmon Dis (2015)

Bottom Line: Multivariable negative binomial regression was performed with adjustment for potential confounding factors.In multivariable negative binomial regression, there was a significant reduction in the expected number of COPD exacerbations among patients who were exposed to TZDs with an incidence rate ratio of 0.86 (95% CI 0.81-0.92).Exposure to TZDs was associated with a small but significant reduction in risk for COPD exacerbation among diabetic patients with COPD.

View Article: PubMed Central - PubMed

Affiliation: Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, CT, USA ; Division of Pulmonary and Critical Care, Yale University, New Haven, CT, USA.

ABSTRACT

Background: Thiazolidinediones (TZDs) are oral antihyperglycemic medications that are selective agonists to peroxisome proliferator-activated receptor gamma and have been shown to have potent anti-inflammatory effects in the lung.

Objective: The purpose of this study was to assess whether exposure to TZDs is associated with a decreased risk of chronic obstructive pulmonary disease (COPD) exacerbation.

Methods: A cohort study was performed by collecting data on all US veterans with diabetes and COPD who were prescribed oral antihyperglycemic medications during from period of October 1, 2005 to September 30, 2007. Patients who had two or more prescriptions for TZDs were compared with patients who had two or more prescriptions for an alternative oral anti-hyperglycemic medication. Multivariable negative binomial regression was performed with adjustment for potential confounding factors. The primary outcome was COPD exacerbations, including both inpatient and outpatient exacerbations.

Results: We identified 7,887 veterans who were exposed to TZD and 42,347 veterans who were exposed to non-TZD oral diabetes medications. COPD exacerbations occurred in 1,258 (16%) of the TZD group and 7,789 (18%) of the non-TZD group. In multivariable negative binomial regression, there was a significant reduction in the expected number of COPD exacerbations among patients who were exposed to TZDs with an incidence rate ratio of 0.86 (95% CI 0.81-0.92).

Conclusion: Exposure to TZDs was associated with a small but significant reduction in risk for COPD exacerbation among diabetic patients with COPD.

No MeSH data available.


Related in: MedlinePlus

Cohort selection.Abbreviations: COPD, chronic obstructive pulmonary disease; TZD, thiazolidinedione.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4536761&req=5

f1-copd-10-1591: Cohort selection.Abbreviations: COPD, chronic obstructive pulmonary disease; TZD, thiazolidinedione.

Mentions: We evaluated 51,216 diabetic veterans who had two or more prescriptions for an oral hypoglycemic agent and a diagnosis of COPD (Figure 1). After excluding patients who received only one prescription for TZDs, we identified 7,887 patients who were exposed to TZDs and 42,347 who were exposed to non-TZD oral diabetes therapy.


Thiazolidinediones are associated with a reduced risk of COPD exacerbations.

Rinne ST, Liu CF, Feemster LC, Collins BF, Bryson CL, O'Riordan TG, Au DH - Int J Chron Obstruct Pulmon Dis (2015)

Cohort selection.Abbreviations: COPD, chronic obstructive pulmonary disease; TZD, thiazolidinedione.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4536761&req=5

f1-copd-10-1591: Cohort selection.Abbreviations: COPD, chronic obstructive pulmonary disease; TZD, thiazolidinedione.
Mentions: We evaluated 51,216 diabetic veterans who had two or more prescriptions for an oral hypoglycemic agent and a diagnosis of COPD (Figure 1). After excluding patients who received only one prescription for TZDs, we identified 7,887 patients who were exposed to TZDs and 42,347 who were exposed to non-TZD oral diabetes therapy.

Bottom Line: Multivariable negative binomial regression was performed with adjustment for potential confounding factors.In multivariable negative binomial regression, there was a significant reduction in the expected number of COPD exacerbations among patients who were exposed to TZDs with an incidence rate ratio of 0.86 (95% CI 0.81-0.92).Exposure to TZDs was associated with a small but significant reduction in risk for COPD exacerbation among diabetic patients with COPD.

View Article: PubMed Central - PubMed

Affiliation: Department of Veterans Affairs, VA Connecticut Healthcare System, West Haven, CT, USA ; Division of Pulmonary and Critical Care, Yale University, New Haven, CT, USA.

ABSTRACT

Background: Thiazolidinediones (TZDs) are oral antihyperglycemic medications that are selective agonists to peroxisome proliferator-activated receptor gamma and have been shown to have potent anti-inflammatory effects in the lung.

Objective: The purpose of this study was to assess whether exposure to TZDs is associated with a decreased risk of chronic obstructive pulmonary disease (COPD) exacerbation.

Methods: A cohort study was performed by collecting data on all US veterans with diabetes and COPD who were prescribed oral antihyperglycemic medications during from period of October 1, 2005 to September 30, 2007. Patients who had two or more prescriptions for TZDs were compared with patients who had two or more prescriptions for an alternative oral anti-hyperglycemic medication. Multivariable negative binomial regression was performed with adjustment for potential confounding factors. The primary outcome was COPD exacerbations, including both inpatient and outpatient exacerbations.

Results: We identified 7,887 veterans who were exposed to TZD and 42,347 veterans who were exposed to non-TZD oral diabetes medications. COPD exacerbations occurred in 1,258 (16%) of the TZD group and 7,789 (18%) of the non-TZD group. In multivariable negative binomial regression, there was a significant reduction in the expected number of COPD exacerbations among patients who were exposed to TZDs with an incidence rate ratio of 0.86 (95% CI 0.81-0.92).

Conclusion: Exposure to TZDs was associated with a small but significant reduction in risk for COPD exacerbation among diabetic patients with COPD.

No MeSH data available.


Related in: MedlinePlus